Deena Maurer, Ph.D.
Parker Institute for Cancer Immunotherapy
San Francisco, CA
Dr. Maurer is a Translational and Regulatory Affairs Scientist Fellow in the Translational Medicine and Regulatory Affairs departments at the Parker Institute for Cancer Immunotherapy (PICI). She focuses on identifying and investigating biomarkers of response to anti-PD-1 treatment in the pancreatic cancer setting. Her work contributes directly to the PRINCE and REVOLUTION pancreatic platform studies. Prior to joining PICI, Dr. Maurer obtained her Ph.D. in microbiology and immunology from the University of Pittsburgh. She has also received her M.S. in biotechnology from Johns Hopkins University, completed a postbaccalaureate fellowship at the U.S. National Institutes of Health studying somatic mutations in endometrial cancer, and received her B.S. from Marywood University.
Diane Da Silva, Ph.D.
Parker Institute for Cancer Immunotherapy
San Francisco, CA
Dr. Da Silva is associate director of translational medicine at the Parker Institute for Cancer Immunotherapy (PICI). She directs the execution of the PICI translational suite of biomarker assays and contributes to disease- and immune-specific biomarker approaches in collaboration with PICI’s clinical and informatics teams. Prior to joining PICI, she was research faculty in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Keck School of Medicine of the University of Southern California (USC). She also served as the scientific director of the Beckman Center for Immune Monitoring at the USC Norris Comprehensive Cancer Center. Dr. Da Silva received her Ph.D. in cancer immunology and immunotherapy from Loyola University Chicago. She completed her National Cancer Institute postdoctoral training fellowship at USC, which focused on identifying mechanisms of viral and tumor immune evasion. She later obtained an M.S. in regulatory science from the USC School of Pharmacy with an emphasis on clinical trial research.
